Regarding CD4 + T-cell subsets, although statistically significant differences were not observed, there was a notable trend towards an increase in activated CD4 + HLA-DR + CD38 + T cells and the subpopulations of Th1 effector memory and Th2 central memory in patients once they are under treatment with omalizumab ( Supplementary Figure S3 ).
← all excerpts
Peripheral blood T-cell modulation by omalizumab in chronic urticaria patients.
1
—
—